Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and systemically deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells, including mRNA, synthetic RNA, DNA, si-RNA, ASOs and gene-editing molecules. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.
Company Details
- Employees
- 9
- Founded
- 2020
- Address
- 311 Pennington Rocky Hill Rd,
- Industry
- Biotechnology
- Website
- http://www.gennao.com
- Keywords
- New York.
- HQ
- Hopewell, New Jersey
Gennao Bio Questions
Gennao Bio's website is http://www.gennao.com
Gennao Bio's LinkedIn profile is https://www.linkedin.com/company/gennao-bio
Gennao Bio has
9 employees.
View email and phone details for 9
employees at Gennao Bio.
Gennao Bio's industry is
Biotechnology
Gennao Bio's top competitors are
Aruvant,
Orbimed,
Ptc Therapeutics, Inc.,
Prelude Therapeutics,
Alexion Pharmaceuticals, Inc.,
Xanadu Bio,
Pyros Pharmaceuticals,
Rocket Pharmaceuticals,
J.p. Morgan Asset Management,
Bristol Myers Squibb.
Gennao Bio's categories are Biotechnology
Gennao Bio's founding year is 2020
